Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). This page aggregates official press releases and verified news about the company’s clinical developments, research breakthroughs, and strategic partnerships.
Investors and industry professionals will find timely updates on ALGS’ pipeline candidates including oral capsid assembly modulators targeting viral suppression in CHB and THR-β agonists addressing liver fat reduction in MASH. The curated news collection provides essential context for understanding clinical trial progress, regulatory milestones, and scientific advancements.
Key content categories include updates on: Phase 1-3 clinical trials, collaborative research initiatives, regulatory communications, and therapeutic mechanism insights. All information is sourced from official company disclosures and reputable industry publications.
Bookmark this page for structured access to ALGS’ evolving scientific narrative. Check regularly for developments in oligonucleotide-based therapies and small molecule candidates progressing through clinical evaluation.
Aligos Therapeutics (Nasdaq: ALGS) has revealed promising new data for its chronic hepatitis B (CHB) treatments at the HEP DART meeting. The Phase 1b study of ALG-000184 demonstrated a high reduction of HBV DNA and RNA in HBeAg-positive patients, similar to results in HBeAg-negative groups. Additionally, preliminary data on a new oral PD-1/PD-L1 antagonist underscores its potential in enhancing immune responses against HBV. Aligos aims to develop a combination therapy approach for functional cures in CHB patients, leveraging various therapeutic candidates.
On November 23, 2021, Vipergen announced a multi-target drug discovery agreement with Aligos Therapeutics (Nasdaq: ALGS). This collaboration utilizes Vipergen's DNA-encoded library (DEL) technology to discover small-molecule compounds targeting specific proteins developed by Aligos for treating viral and liver diseases. Aligos will maintain exclusive rights for global commercialization of any resulting products. Financial details remain undisclosed, but Vipergen aims to enhance Aligos' drug portfolio, addressing critical health needs in chronic hepatitis B, NASH, and coronavirus.
Aligos Therapeutics (Nasdaq: ALGS) announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, 2021. The presentation will be available as a webcast starting November 22, 2021, at 10:00 AM EST, with a replay accessible for 90 days. Aligos management will also hold virtual investor meetings during the conference. For more details, visit the Aligos website or contact your Piper Sandler representative.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the appointment of Dr. Bridget Martell to its board of directors. Dr. Martell brings extensive experience in therapeutics development, having contributed to six marketed products and held leadership roles in various biopharmaceutical companies. CEO Lawrence Blatt emphasized her role in advancing Aligos's therapeutic candidates for chronic hepatitis B and NASH through clinical trials. Aligos aims to be a leader in treating viral and liver diseases with innovative therapies.
On November 15, 2021, Aligos Therapeutics announced that CEO Lawrence M. Blatt will present at the Jefferies London Healthcare Conference on November 18-19, 2021. The company, listed on Nasdaq under the ticker ALGS, focuses on developing innovative treatments for viral and liver diseases. A webcast of the presentation will be available starting November 18, 2021, at 8:00 AM GMT with a replay accessible for 30 days. Interested investors can schedule virtual one-on-one meetings through their Jefferies representatives.
Aligos Therapeutics (Nasdaq: ALGS) announced significant advancements in its hepatitis B virus (HBV) treatment pipeline at The Liver Meeting 2021. The company presented promising results for its capsid assembly modulator (CAM) candidate, ALG-000184, which showed rapid reductions in HBV DNA and RNA after 28 days of oral dosing. Aligos also highlighted the synergistic potential of its multi-modal approach to enhance treatment effectiveness for chronic hepatitis B (CHB). Additionally, preclinical findings on several candidates, including STOPS™ and ALG-055009, demonstrated favorable pharmacokinetic profiles.
Aligos Therapeutics (Nasdaq: ALGS) reported its Q3 2021 financial results, revealing a net loss of $33.1 million, slightly lower than the $33.3 million loss in Q3 2020. R&D expenses rose to $28.1 million from $17.3 million, driven by ongoing clinical trials for its hepatitis B therapies. The company is advancing its drug candidates, including ALG-020572 and ALG-055009, with patient enrollment progressing. Notably, cash reserves stand at $242.7 million, maintaining a stable financial position despite increased expenditures.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that it will release its third quarter 2021 financial results on November 4, 2021, following U.S. market close. Founded in 2018, Aligos is a clinical-stage biopharmaceutical company aiming to lead in treatments for viral infections and liver diseases. The company is focused on developing targeted antiviral therapies for chronic hepatitis B and coronaviruses, alongside therapeutics for nonalcoholic steatohepatitis (NASH).
Aligos Therapeutics (Nasdaq: ALGS) announced its participation in The Liver Meeting® 2021, presenting data on chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) programs. The virtual event will take place from November 12-15, 2021. Key presentations include:
- Safe and effective Capsid Assembly Modulator (ALG-000184) for CHB
- Innovative Antisense Oligonucleotides showing significant efficacy
- Preclinical results for treatment of NASH with ALG-055009.
All poster data will be available post-conference on the Aligos website.
Aligos Therapeutics (Nasdaq: ALGS) is advancing three of its four drug candidates for chronic hepatitis B (CHB) to clinical trials. The latest candidate, ALG-020572, is being evaluated in a Phase 1 study starting with healthy volunteers. This proprietary antisense oligonucleotide aims to lower HBsAg levels, potentially leading to a functional cure in CHB patients. Aligos believes that ALG-020572 might possess enhanced antiviral activity compared to other candidates. The company is also pursuing various mechanisms within its CHB portfolio for improved treatment outcomes.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
